EDITORIAL SECTION
-
STRATEGY
Strategic Positioning for M&A
The biotechnology sector is characterised by a constant influx of small highly specialised companies
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solutions help reduce contamination risk and lower manual handling
-
CLINICAL TRIALS
Virtual Clinical Trials
Virtual digital and decentralized are all descriptions of the novel ways that using technology changes
-
Bio Pharma
Biosimilars and Biobetters
Biosimilars are biologic medical products that are essentially identical to an original product manufactured
-
MANUFACTURING
Transformative Convergence of AI in Pharmaceutical Manufacturing
The pharmaceutical manufacturing industry is on the cusp of a revolutionary transformation driven by
-
Information Technology
Transformative Impact of Artificial Intelligence on Clinical Trials
Artificial Intelligence AI has rapidly evolved from a futuristic concept to a transformative tool across various industries
-
EXPERT Talk
Advancing Biopharmaceutical Innovation Through Cell Encapsulation and Biomimetic Therapeutic Systems
My interest in biopharmaceutical engineering began during my senior year as an undergraduate For my capstone project I worked on the encapsulation of...
Advisory Board
.webp "Juris Hmelnickis")
.webp "Eiman Shafa")
KNOWLEDGE BANK
-
Articles
AI-Powered Clinical Trials: Accelerating Study Design and Execution
For more than a decade the industrys capital and attention have flowed toward the front of the pipeline Target identification generative chemistry and structural prediction have all been genuinely transformed Yet the median interval from firstinhuman dosing to approval has barely moved The reason is uncomfortable but well understood inside every development committee the constraint is no longer fi...
-
Techno Trends
University Researchers Develop CAR T Therapy Candidate for Solid Tumour Treatment
Researchers from the University of Calgary and McMaster University have developed a novel CAR T cell therapy approach targeting treatmentresistant solid tumours
-
Projects
BeOne Medicines Invests US$300 Million to Expand New Jersey Manufacturing Campus
BeOne Medicines has announced a US million expansion of its Princeton West Innovation Campus in Hopewell New Jersey strengthening its US manufacturing and research capabilities
-
Research Insights
Thymidylate synthase inhibitory drugs induce p53-dependent pathways differently
Thymidylate synthase TS is a key enzyme in thymidylate biosynthesis and an established target of chemotherapeutics such as fluorodeoxyuridine FdUR and raltitrexed RTX Inhibition of TS disrupts
-
White Papers
Accelerating In-Vitro Antibody Discovery with Artificial Intelligence
Antibodies have transformed modern medicine reshaping treatment paradigms across autoimmune disorders oncology and infectious diseases As one of the most versatile and successful therapeutic modalities
TOP ARTICLES
-
1
Autoantigen-Specific Biomarkers as Effector-Driven Therapeutic Targets
Lakshmi
For decades, autoantibodies were read as clues — signposts pointing to a disease already underway. A new generation of science is asking a sharper question: what if the biomarker is not just a s...
-
2
Global Regulatory Harmonization Strategies for Multi-Region Drug Approvals
Kate Williamson
Integrating Multiregional drug approvals Global regulatory harmonization is simplifying drug approvals across the globe, harmonizing global standards, extending submissions, complicated the developmen...
-
3
Twin-Screw Melt Granulation: A Solvent-Free, Single-Step Solution for Enhancing Drug Solubility
Dinesh Nyavanandi
Nithin Vidiyala
Twin-screw melt granulation (TSMG) is a solvent-free, single-step, and scalable technology enhancing solubility and bioavailability of poorly water-soluble APIs. By improving dissolution, process effi...
-
4
One Health and Antimicrobial Resistance
Ramendra Pati Pandey
Gajala Deethamvali Ghouse Peer
Carlos R Prudencio
Antonio Charlys da Costa
Elcio Leal
Chung-Ming Chang
It is for the most part recognized that we share many elements with other creature species, which are surely pertinent when the ideas of health and disease are talked about. The term 'One Health&#...
-
5
RNA Revolution: Advancing Drug Discovery through Targeted Molecules
Kate Williamson
The RNA revolution in drug discovery has introduced targeted molecules like ASOs, siRNA, and RNA vaccines, offering precise gene modulation and therapeutic versatility across genetic disorders, neurod...
press releasesRead more...
Revolution Medicines and BeOne Medicines Announce Clinical Development and Regional Commercialization Collaboration
Revolution Medicines Inc a latestage clinical oncology company developing targeted therapies for patients with RASaddicted cancers and BeOne Medicines Ltd Nasdaq ONC HKEX SSE
Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader
Amneal Pharmaceuticals Inc Amneal or the Company NASDAQ AMRX today announced the completion of its acquisition of Kashiv BioSciences LLC Kashiv creating a fully integrated global biosimilars
Xcellon Biologics Acquires GMP Manufacturing Facility from NextCure, Becoming an End-to-End CRDMO for Next-Generation Bioconjugates and Complex Biologics
Xcellon Biologics a USbased Contract Research Development and Manufacturing Organization CRDMO specializing in bioconjugates and complex biologics today announced that it has signed
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film
Aquestive Therapeutics Inc NASDAQ AQST Aquestive or the Company a pharmaceutical company advancing medicines to bring meaningful improvement to patients lives through innovative science
Events Read more...
11 - 12
Aug 2026Medical Device Safety Monitoring and Reporting
San Diego, CA, USA
19 - 21
Aug 2026ISPE Conference & Exhibition 2026
Suntec Singapore
20 - 21
Aug 2026Pharmaceutical Formulations 2026
London, UK
20 - 21
Aug 2026Novel Drug Delivery Systems 2026
London, UK
20 - 21
Aug 2026Advanced Clinical Research 2026
London, UK
25 - 27
Aug 2026CPHI Korea 2026
COEX, Seoul, Korea
26 - 27
Aug 2026BIOMEDevice 2026
Boston Convention & Exhibition...
03 - 05
Sep 20265th MENA Congress for Rare Diseases 2026
Beach Rotana Hotel, Abu Dhabi,...
LATEST NEWSRead more...
Spyre Therapeutics Launches SPY772 Programme and Begins Phase 2 Trial in Hidradenitis Suppurativa
Spyre Therapeutics has launched SPY a new combination programme designed to target two inflammatory pathways involved in immunemediated diseases The company has also started the Phase SKYLIGHT trial to assess the approach in patients with hidradenitis suppurativa HS
Acurx Partners with Leiden University Medical Center to Advance Antibiotic Development
Acurx Pharmaceuticals has entered into a scientific partnership with Leiden University Medical Center LUMC in the Netherlands to advance the development of its DNA polymerase IIIC PolC inhibitor antibiotics for difficulttotreat bacterial infections
Bristol Myers Squibb to Invest $2.3 Billion in New Manufacturing Campus in Houston, Texas
Bristol Myers Squibb BMS has selected Houston Texas as the location for a new multimodal manufacturing campus representing an investment of approximately billion
Greenstone Biosciences Secures NIH R61 Grant to Develop Treatments for Duchenne Muscular Dystrophy-Related Heart Disease
Greenstone Biosciences has received a Catalyze R grant from the National Heart Lung and Blood Institute NHLBI part of the US National Institutes of Health NIH to support the discovery of new treatments for myocardial fibrosis and dilated cardiomyopathy associated with Duchenne muscular dystrophy DMD
Schrödinger and Bristol Myers Squibb expand collaboration to deploy AI co-scientist for drug discovery
Schrdinger has entered into a strategic collaboration and software agreement with Bristol Myers Squibb BMS to deploy its agentic AI coscientist Bunsen across the companys research organisation to support drug discovery
US FDA approves Takeda's ORZEYFUL for narcolepsy type 1
Takeda has received approval from the US Food and Drug Administration FDA for ORZEYFUL oveporexton making it the first and only treatment approved to address the underlying cause of narcolepsy type NT in adults
